Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Pharmaceuticals plc

https://www.hikma.com/

Latest From Hikma Pharmaceuticals plc

Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market

Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.

Financing Business Strategies

Can The Pipeline Soothe A US Generics Pricing Headache?

Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.

Generic Drugs Sales & Earnings

Glenmark Chief: Running A Facility In The US Has Been A Struggle

Glenmark readies scale up in the respiratory segment, with Ryaltris set for a US debut and a filing for a generic rival to Flovent anticipated. Running a facility in that market, though, is not an easy task, says the firm's leadership.

Manufacturing Sales & Earnings

Can The Pipeline Soothe A US Generics Pricing Headache?

Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.

Generic Drugs Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Custopharm, Inc.
    • EIMC United Pharmaceuticals
    • Roxane Laboratories, Inc.
    • West-Ward Pharmaceuticals Corp.
UsernamePublicRestriction

Register